Insilico Medicine’s AI-Discovered CKD Anemia Drug ISM4808 Enters Phase I Clinical Trials

Insilico Medicine’s AI-Discovered CKD Anemia Drug ISM4808 Enters Phase I Clinical Trials

By, Admin 9 March 2026

Clinical-stage biotech company Insilico Medicine has announced the first clinical milestone for ISM4808, an AI-discovered drug candidate for chronic kidney disease (CKD)-related anemia.

The program, previously licensed to TaiGen Biotechnology, has now enrolled and dosed the first participant in its Phase I clinical trial, marking the therapy’s transition from AI-driven discovery to human testing.

This milestone highlights the growing role of artificial intelligence in accelerating drug discovery and clinical development.

AI-Designed Drug Targeting CKD-Related Anemia

ISM4808 is an investigational oral hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor designed to treat anemia associated with chronic kidney disease.

The drug was discovered using Insilico’s generative chemistry platform, Chemistry42.

Unlike traditional erythropoiesis-stimulating agents (ESAs) that require injections, ISM4808 works by stimulating the body’s natural production of erythropoietin (EPO).

Potential benefits include:

  • Oral administration instead of intravenous injections
  • Improved iron utilization
  • A potentially favorable safety profile
  • Enhanced convenience for patients

These advantages could help address limitations associated with current CKD anemia treatments.

Addressing a Growing CKD Burden in Greater China

Chronic kidney disease continues to rise across the Greater China region, creating increasing demand for improved treatment options.

Key statistics highlight the scale of the problem:

  • More than 1 in 7 CKD patients develop anemia
  • CKD-related anemia significantly impacts patient quality of life and disease progression

A safer and more convenient oral therapy like ISM4808 could play an important role in managing this complication.

Licensing Deal Between Insilico and TaiGen

In December 2025, Insilico Medicine signed a licensing agreement with TaiGen Biotechnology to advance the drug’s development.

Under the agreement:

  • TaiGen obtained exclusive rights to develop and commercialize ISM4808 in Greater China, including:
    • Mainland China
    • Hong Kong
    • Macau
    • Taiwan
  • Insilico is eligible to receive:
    • Upfront payments
    • Development and sales milestone payments
    • Tiered royalties on net sales

The total deal value is reported to reach tens of millions of US dollars.

Rapid Progress Into Clinical Testing

Following the licensing agreement, TaiGen moved quickly to advance the program.

Within three months, the company completed regulatory preparation and successfully enrolled the first patient in the Phase I trial.

The study is designed as a randomized, double-blind, placebo-controlled clinical trial and includes:

  • Single Ascending Dose (SAD) cohorts
  • Multiple Ascending Dose (MAD) cohorts

The trial aims to evaluate:

  • Safety
  • Tolerability
  • Pharmacokinetics of ISM4808 in healthy adult volunteers

Expanding the Pipeline of AI-Discovered Drugs

ISM4808 is part of Insilico Medicine’s growing pipeline of AI-driven therapeutics.

Another candidate discovered using the Chemistry42 platform is Garutadustat, a PHD-targeting drug currently being developed for Inflammatory Bowel Disease.

The Phase II clinical trial for garutadustat began dosing patients in January 2026. This progress demonstrates how AI-powered discovery platforms can shorten the timeline from drug concept to clinical testing.

About Insilico Medicine

Insilico Medicine is a global biotechnology company focused on AI-driven drug discovery and development.

The company integrates:

  • Artificial intelligence
  • Automation technologies
  • Internal drug discovery capabilities

These technologies are used to develop new treatments for areas such as:

  • Fibrosis
  • Oncology
  • Immunology
  • Pain
  • Obesity and metabolic disorders

Insilico was listed on the Hong Kong Stock Exchange on December 30, 2025.

Bottom line

The first patient dosing in the Phase I trial of ISM4808 marks an important milestone for Insilico Medicine’s AI-powered drug discovery platform, bringing a potential next-generation oral therapy for CKD-related anemia closer to clinical validation.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!